Key facts
- This page summarizes Powl Brian T.'s Form 4 filing for FATE THERAPEUTICS INC (FATE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2023, 17:19.
Powl Brian T. - 05 Jul 2023 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- FATE
- Reported as of
- 05 Jul 2023
- Net transaction value
- -$18,769
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2023, 17:19:21 UTC
- Prior SEC filing
- 07 Feb 2023
- Next SEC filing
- 16 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cindy Tahl, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Powl Brian T. filed Form 4 for FATE THERAPEUTICS INC (FATE) on 06 Jul 2023.
Change
- Previous filing in this sequence was filed on 07 Feb 2023.
- Current net transaction value: -$18,769.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FATE
transaction
Common Stock
Sale
- Transaction value
- $18,769
- Shares
- -3,854
- Change %
- -8.6%
- Price
- $4.87
- Shares after
- 41,146
- Date
- 05 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 11,250 shares of Common Stock underlying RSUs granted to the Reporting Person on June 27, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
Footnote F2
Represents the weighted average sale price of the shares sold from $4.82 to $4.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth this footnote.